Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT …
Background This document is a summary of the French intergroup guidelines regarding the
management of pancreatic adenocarcinoma (PA), updated in July 2018. Design This …
management of pancreatic adenocarcinoma (PA), updated in July 2018. Design This …
[HTML][HTML] Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report
MJ Duffy, C Sturgeon, R Lamerz, C Haglund… - Annals of oncology, 2010 - Elsevier
Pancreatic ductal adenocarcinoma is one of the most difficult malignancies to diagnose and
treat. The aim of this article is to review how tumor markers can aid the diagnosis and …
treat. The aim of this article is to review how tumor markers can aid the diagnosis and …
Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer
V Heinemann, S Boeck, A Hinke, R Labianca, C Louvet - BMC cancer, 2008 - Springer
Background Single-agent gemcitabine (GEM) is a standard treatment for advanced and
metastatic pancreatic cancer. This study examines the question whether GEM-based …
metastatic pancreatic cancer. This study examines the question whether GEM-based …
[PDF][PDF] Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic …
G Colucci, R Labianca, F Di Costanzo, V Gebbia… - 2010 - academia.edu
Purpose Single-agent gemcitabine became standard first-line treatment for advanced
pancreatic cancer after demonstration of superiority compared with fluorouracil. The Gruppo …
pancreatic cancer after demonstration of superiority compared with fluorouracil. The Gruppo …
[PDF][PDF] Designing platinum compounds in cancer: structures and mechanisms
T Boulikas, A Pantos, E Bellis, P Christofis - Cancer Ther, 2007 - regulon.com
Chemotherapy, surgery and radiotherapy continue to be the mainstay treatments of cancer.
Over 700 FDA-approved drugs have entered into clinical practice during the last 30 years …
Over 700 FDA-approved drugs have entered into clinical practice during the last 30 years …
Half-antibody functionalized lipid− polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells
Current chemotherapy regimens against pancreatic cancer are met with little success as
poor tumor vascularization significantly limits the delivery of oncological drugs. High-dose …
poor tumor vascularization significantly limits the delivery of oncological drugs. High-dose …
Systemic therapy for biliary tract cancers
AF Hezel, AX Zhu - The oncologist, 2008 - academic.oup.com
Abstract Learning Objectives After completing this course, the reader will be able to: Assess
the clinical and molecular heterogeneity of BTCs. Exploit the chemotherapy responsiveness …
the clinical and molecular heterogeneity of BTCs. Exploit the chemotherapy responsiveness …
Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer
The selective MEK1/2 inhibitor pimasertib has shown anti‐tumour activity in a pancreatic
tumour model. This phase I/II, two‐part trial was conducted in patients with metastatic …
tumour model. This phase I/II, two‐part trial was conducted in patients with metastatic …
[HTML][HTML] Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials
BACKGROUND: Pancreatic cancer is the fourth leading cause of cancer-related death
worldwide. Gemcitabine is the mainstay treatment for advanced disease. However, almost …
worldwide. Gemcitabine is the mainstay treatment for advanced disease. However, almost …
Chemotherapy regimens for advanced pancreatic cancer: a systematic review and network meta-analysis
Background Advanced pancreatic cancer confers poor prognosis and treatment
advancement has been slow. Recent randomized clinical trials (RCTs) have demonstrated …
advancement has been slow. Recent randomized clinical trials (RCTs) have demonstrated …